Tirzepatide
- ✅ 99% Purity – Third-Party Tested
- 🚚 Free U.S. Shipping on Orders $100+
Proudly Made in the USA- ⚡ Fast & Reliable Shipping
- 🔒 Secure Checkout Guaranteed
Strength: —
⚗ For laboratory research use only. Not for human consumption. Certificate of Analysis available for this batch.
What Is Tirzepatide?
Tirzepatide (LY3298176) is a synthetic 39-amino-acid dual GIP/GLP-1 receptor agonist peptide, often called a "twincretin." It is investigated in preclinical and in-vitro incretin-signalling research. Tirzepatide is a research compound not approved by the FDA for human or veterinary use. It is supplied strictly for laboratory research only.
Disclaimer: Tirzepatide is a research compound not approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use. It is not intended to diagnose, treat, cure, or prevent any disease. This product is strictly for laboratory research purposes only.
Research-grade Tirzepatide supplied by RCDbio is not a pharmaceutical product, is not a dietary supplement, and is not intended for self-administration. The pharmaceutical formulations of tirzepatide (marketed as Mounjaro and Zepbound by Eli Lilly and Company) are separate, FDA-approved products at defined doses and are distinct from research-grade material. This page describes the compound as a reference reagent for qualified research entities only.
Chemical & Structural Properties
Property | Detail |
|---|---|
Product Type | Synthetic dual receptor agonist peptide (GIP/GLP-1, twincretin) |
Product Name | Tirzepatide |
Application | Scientific / research use only |
CAS Number | 2023788-19-2 |
Molar Mass | 4813.527 g/mol (free base) |
Chemical Formula | C₂₂₅H₃₄₈N₄₈O₆₈ |
PubChem CID | 156588324 |
Amino Acid Count | 39 amino acids (GIP-backbone derived; C-terminal amide) |
Non-Coded Residues | Aib at positions 2 and 13 (DPP-4 resistance) |
Lipid Conjugate | C20 fatty diacid via (AEEA)₂-γGlu linker at Lys20 epsilon-amino group |
Receptor Targets | GIPR (affinity ~ native GIP); GLP-1R (~18–20× weaker than native GLP-1; biased toward cAMP vs β-arrestin) |
Synonyms | LY3298176; twincretin; Mounjaro / Zepbound (pharmaceutical formulations) |
Elimination Half-Life | ~5 days (albumin binding via C20 fatty diacid) |
Physical Form | Lyophilized white to off-white powder |
Solubility | Soluble in sterile water and PBS; compatible with standard peptide reconstitution buffers |
Storage (Lyophilized) | −20°C; sealed, light-protected container with desiccant |
Storage (Reconstituted) | 4°C; use within 48–72 hours; avoid repeated freeze-thaw cycles |
Purity | ≥98% (HPLC verified; third-party laboratory analysis; COA available per batch) |
WADA Status | Prohibited under S2 and S0 (2026 WADA Prohibited List); research-grade material is not TUE-eligible. Verify at GlobalDRO.com. |
Tirzepatide Research Background
Tirzepatide (LY3298176) was developed by Eli Lilly and Company as a single-molecule dual incretin receptor agonist engineered on the endogenous GIP peptide backbone. Its amino acid sequence incorporates two non-coded 2-aminoisobutyric acid (Aib) residues at positions 2 and 13 to confer resistance to dipeptidyl peptidase-4 (DPP-4) degradation, and a C20 fatty diacid moiety conjugated via a (AEEA)₂-γGlu linker at the Lys20 epsilon-amino group to promote albumin binding. As a defined dual-agonist reference compound, it is widely studied in molecular pharmacology and metabolic-signalling research Willard et al., 2020.
The pharmaceutical formulation received FDA approval on May 13, 2022 (Mounjaro, type 2 diabetes) and in November 2023 (Zepbound, chronic weight management). These approvals apply only to the defined pharmaceutical doses; research-grade Tirzepatide is a separate, non-approved reagent for laboratory use.
How Does Tirzepatide Work? Mechanism of Action
Tirzepatide mechanistically engages two incretin receptor systems — the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R) — with an "imbalanced" pharmacological profile characterised in receptor-binding and signalling studies. Findings below are observed in preclinical and in-vitro models and are not claims of efficacy for research-grade material.
Structurally, the peptide docks at the orthosteric binding pocket of each class-B G-protein-coupled receptor, initiating a conformational shift in the transmembrane helix bundle that couples to Gαs and drives adenylate-cyclase activation and cAMP generation via the PKA cascade. At GIPR, Tirzepatide shows binding affinity comparable to native GIP. At GLP-1R, its affinity has been reported as approximately 18–20× weaker than native GLP-1 — the basis of the "imbalanced" descriptor Willard et al., 2020.
At the GLP-1R specifically, Tirzepatide displays biased agonism: it favours cAMP generation over β-arrestin recruitment and shows weaker receptor internalisation than native GLP-1. This signalling bias is investigated as a mechanistic distinction from semaglutide and endogenous GLP-1 Willard et al., 2020. The C20 fatty diacid at Lys20 non-covalently binds circulating albumin, reducing renal filtration and extending the pharmacological half-life to approximately 5 days in pharmacokinetic studies — enabling once-weekly dosing in the approved pharmaceutical protocols.
Key Research Areas for Tirzepatide
The table below summarises areas in which Tirzepatide is investigated as a reference compound. These are observations from preclinical, in-vitro, and controlled clinical research contexts and do not constitute claims of efficacy or safety for research-grade material.
Area of Research | Research Note |
|---|---|
Dual-receptor & biased-signalling pharmacology | Primary reference twincretin in receptor-binding assays, cAMP reporter systems, and β-arrestin recruitment assays characterising imbalanced GIPR/GLP-1R engagement Willard et al., 2020. |
Incretin biology & insulin-secretion dynamics | Studied in isolated pancreatic beta-cell preparations and rodent models for glucose-dependent insulin-secretion pathways under GIP/GLP-1 co-activation. |
Metabolic & adipose-tissue signalling | Investigated in preclinical models for energy-homeostasis and hypothalamic appetite-circuit pathways; body-weight observations recorded in the pharmaceutical SURMOUNT clinical programme Jastreboff et al., 2022. |
Comparative incretin pharmacology (SAR) | Employed as a dual-agonist benchmark against GLP-1R monoagonists (semaglutide, liraglutide) and the triple agonist retatrutide in structure-activity studies. |
Tirzepatide vs Semaglutide vs Retatrutide (Research Comparison)
The comparison below is provided for research contextualization within incretin pharmacology. It is not a therapeutic comparison and does not imply any human use of research-grade material.
Property | Tirzepatide | Semaglutide | Retatrutide |
|---|---|---|---|
Receptor class | Dual GIP/GLP-1 agonist ("twincretin") | GLP-1R monoagonist | Triple GIP/GLP-1/glucagon agonist |
GLP-1R signalling | Biased toward cAMP over β-arrestin | Balanced/native-like | Under characterisation |
Approx. reported half-life | ~5 days | ~7 days | ~6 days |
Albumin-binding motif | C20 fatty diacid at Lys20 | C18 fatty diacid | Fatty-acid conjugate |
Research framing | Reference dual agonist | Reference monoagonist | Reference triple agonist |
What Are the Risks and Limitations of Tirzepatide Research?
This section is mandatory reading before working with Tirzepatide in any laboratory setting. Risk tier: MODERATE.
Handling Precautions: Tirzepatide should be handled by trained laboratory personnel only, in a controlled research environment. Use appropriate PPE at all times — nitrile gloves, laboratory coat, and eye protection at minimum. Handle lyophilized powder in a laminar flow cabinet or clean area, avoid aerosol generation during reconstitution, and avoid direct skin contact or inhalation of any reconstituted solution.
Exposure Risks: Tirzepatide is a pharmacologically active dual incretin receptor peptide thought to engage GIPR and GLP-1R in tissues expressing them; accidental exposure at research concentrations may produce incretin-consistent effects. No human safety data exists for research-grade material outside approved clinical protocols.
Storage: Store lyophilized Tirzepatide at −20°C in a dry, dark environment with desiccant. Store reconstituted material at 4°C and use within 48–72 hours. Protect from light, heat, moisture, and oxidative conditions; the peptide backbone and fatty-acid conjugate may both degrade with repeated freeze-thaw cycles. The amphiphilic conjugate can adsorb to some surfaces — avoid lipophilic-binding containers.
Toxicity and Data Limitations: No chronic toxicity data exist for research-grade Tirzepatide. Adverse-event observations (gastrointestinal effects, hypoglycaemia risk when combined with insulin, injection-site reactions, transient heart-rate increase, pancreatitis signals, and rodent thyroid C-cell findings) derive from pharmaceutical-formulation clinical trials and should not be extrapolated to research-grade material. All findings are from short-duration or controlled-protocol contexts only.
Frequently Asked Questions
Q: What is Tirzepatide investigated for in research?
Tirzepatide (LY3298176) is a synthetic 39-amino-acid dual GIP/GLP-1 receptor agonist peptide. In laboratory and in-vitro contexts it is investigated for dual incretin-receptor pharmacology, biased GLP-1R signalling, and insulin-secretion dynamics. Research-grade material is not approved for human use.
Q: How does Tirzepatide differ from semaglutide?
Semaglutide is a GLP-1R monoagonist. Tirzepatide adds GIPR agonism as a second mechanism (twincretin) and, at GLP-1R, shows biased signalling toward cAMP over β-arrestin recruitment. This mechanistic distinction is studied in molecular pharmacology models; it is not a therapeutic comparison.
Q: What is the half-life of Tirzepatide in vitro?
Pharmacokinetic studies report an elimination half-life of approximately 5 days, attributed to the C20 fatty diacid at Lys20 promoting albumin binding and reducing renal filtration. This value derives from pharmaceutical-formulation studies and is provided as reference data only.
Q: How should research-grade Tirzepatide be stored?
Store lyophilized Tirzepatide at −20°C in a sealed, light-protected container with desiccant. Once reconstituted, store at 4°C and use within 48–72 hours. Avoid repeated freeze-thaw cycles, as both the peptide backbone and fatty-acid conjugate may degrade.
Q: Is Tirzepatide approved by the FDA?
The pharmaceutical formulations (Mounjaro, 2022; Zepbound, 2023) are FDA-approved at defined doses. Research-grade Tirzepatide is a separate, non-approved reagent and is not intended for human or veterinary use.
Q: What is Tirzepatide's WADA status?
Tirzepatide is prohibited under S2 (peptide hormones and related substances) and S0 (non-approved substances) of the 2026 WADA Prohibited List. Research-grade material is not TUE-eligible. Verify current status at GlobalDRO.com.
What to Look for in a Supplier When Sourcing Research-Grade Tirzepatide
Check that every batch is independently third-party tested for purity and identity, and that a Certificate of Analysis (COA) is available for each lot. Prefer suppliers that sell strictly for preclinical and in-vitro research use. You can consider verified suppliers such as RCDbio, where all compounds are supplied strictly for preclinical and in-vitro research use.
Note: All products referenced are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human or veterinary purposes.
Disclosure: This content is for informational purposes only and does not constitute an endorsement of any product for human use.
References
1). Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526454/
2). Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. https://pubmed.ncbi.nlm.nih.gov/35658024/
ATTENTION: This content is for LABORATORY AND RESEARCH PURPOSES ONLY. Not for human or veterinary use. Educational purpose only. No human consumption.